thiophenes has been researched along with Ascites in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (83.33) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belotti, D; Garofalo, A; Giavazzi, R; Manenti, L; Marchini, S; Paganoni, P; Taraboletti, G | 1 |
Brown, PD; Talbot, DC | 1 |
Parsons, SL; Steele, RJ; Watson, SA | 1 |
Beattie, GJ; Smyth, JF | 1 |
Bone, EA; Dickson, RB; Johnson, MD; Low, JA | 1 |
1 review(s) available for thiophenes and Ascites
Article | Year |
---|---|
Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Ascites; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Extracellular Matrix; Female; Humans; Male; Metalloendopeptidases; Mice; Middle Aged; Neoplasms; Phenylalanine; Pleural Effusion, Malignant; Protease Inhibitors; Rats; Thiophenes | 1996 |
2 trial(s) available for thiophenes and Ascites
Article | Year |
---|---|
Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
Topics: Aged; Antineoplastic Agents; Ascites; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Metalloendopeptidases; Middle Aged; Phenylalanine; Protease Inhibitors; Thiophenes; Treatment Outcome | 1997 |
Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Dose-Response Relationship, Drug; Female; Humans; Male; Metalloendopeptidases; Middle Aged; Neoplasms; Phenylalanine; Protease Inhibitors; Thiophenes | 1998 |
3 other study(ies) available for thiophenes and Ascites
Article | Year |
---|---|
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Topics: Animals; Ascites; Cell Movement; Culture Media, Conditioned; Endothelial Growth Factors; Enzyme Activation; Female; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Ovarian Neoplasms; Peritoneal Cavity; Phenylalanine; Thiophenes; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Topics: Animals; Antineoplastic Agents; Ascites; Female; Gelatinases; Humans; Mammary Neoplasms, Experimental; Metalloendopeptidases; Mice; Mice, Nude; Neoplasm Transplantation; Phenylalanine; Protease Inhibitors; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
Batimastat. BB 94, collagenase inhibitors-1.
Topics: Animals; Antineoplastic Agents; Ascites; Drugs, Investigational; Humans; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Mice; Neoplasms; Phenylalanine; Pleural Effusion, Malignant; Protease Inhibitors; Thiophenes | 1999 |